KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accumulated Depreciation (2017 - 2021)

Historic Accumulated Depreciation for Aquestive Therapeutics (AQST) over the last 5 years, with Q1 2021 value amounting to $37.8 million.

  • Aquestive Therapeutics' Accumulated Depreciation fell 238.92% to $37.8 million in Q1 2021 from the same period last year, while for Mar 2021 it was $37.8 million, marking a year-over-year decrease of 238.92%. This contributed to the annual value of $40.9 million for FY2020, which is 744.93% up from last year.
  • Aquestive Therapeutics' Accumulated Depreciation amounted to $37.8 million in Q1 2021, which was down 238.92% from $40.9 million recorded in Q4 2020.
  • In the past 5 years, Aquestive Therapeutics' Accumulated Depreciation ranged from a high of $40.9 million in Q4 2020 and a low of $32.0 million during Q4 2017
  • For the 5-year period, Aquestive Therapeutics' Accumulated Depreciation averaged around $37.0 million, with its median value being $37.3 million (2019).
  • As far as peak fluctuations go, Aquestive Therapeutics' Accumulated Depreciation soared by 995.47% in 2018, and later plummeted by 238.92% in 2021.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Accumulated Depreciation stood at $32.0 million in 2017, then rose by 9.95% to $35.2 million in 2018, then rose by 8.11% to $38.0 million in 2019, then grew by 7.45% to $40.9 million in 2020, then fell by 7.45% to $37.8 million in 2021.
  • Its Accumulated Depreciation stands at $37.8 million for Q1 2021, versus $40.9 million for Q4 2020 and $40.2 million for Q3 2020.